Research blog
May 11, 2026 Research use only

Ipamorelin Research Notes: Scientific Literature, Assay Context, and References

Ipamorelin research notes covering scientific literature context, assay variables, analytical documentation, and selected references for laboratory audiences only.

Ipamorelin 2D compound structure
Research-use-only scope: This article provides source and terminology context for laboratory review. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.

Ipamorelin appears in the literature as a growth hormone secretagogue. The references below were selected because they name Ipamorelin directly rather than discussing the broader ghrelin system alone.

Ipamorelin 2D compound structure
Ipamorelin structure reference. Source: PubChem CID 9831659.

Reading Ipamorelin sources carefully

The papers use different study designs, including receptor-selectivity work and pharmacokinetic research. Results from one design should not be transferred to another without reviewing the methods, model, controls, and limitations.

Verified references

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822. DOI: 10.1530/eje.0.1390552.
  2. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999. PMID: 10496658. DOI: 10.1023/A:1018955126402.
  3. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998. PMID: 9879640. DOI: 10.1080/004982598238976.

Product documentation is separate

Published papers do not identify a BioPep USA lot. Use the Ipamorelin product page for current catalog options and the documentation page for the matching lot, purity result, and analysis date.

Last source review: July 20, 2026.